The forward P/E of 19.7x implies a modest de-rating, but the EV/EBITDA multiple of 15.1x is at a premium to Cardinal Health's 20.0x, suggesting the market already credits McKesson with superior growth and profitability. However, the P/S of 0.26x underscores the low-margin distribution model, making earnings-based multiples more meaningful. The 18% adjusted EPS growth in fiscal 2026, as reported, supports a growth premium, but investors should monitor whether the specialty mix can sustain this trajectory.

The 100 basis point decline in gross margin likely reflects a higher proportion of low-margin distribution volume, but the operating margin stability suggests cost discipline and mix benefits from RxTS and oncology. Net margin of 0.6% in 2027Q1 is depressed by non-operating items, as evidenced by the swing from 1.7% in 2026Q4. Adjusted EPS growth of 18% in fiscal 2026, as reported, indicates that underlying profitability is improving, but the thin absolute margins leave little room for error.

The wide quarterly swings in ROIC, ranging from 18.7% to 39.9%, are not indicative of a deteriorating franchise but rather reflect the lumpy nature of capital deployment and the asset-light model. The average ROIC over the period is approximately 27%, which is strong and suggests the company is compounding returns on invested capital. However, the negative equity position complicates ROE analysis, making ROIC a more reliable metric for assessing value creation.

The negative CCC indicates that McKesson collects from customers and turns inventory before paying suppliers, effectively using supplier financing to fund operations. DPO has remained stable around 54-59 days, while DIO has compressed from 27 to 23 days, reflecting efficient inventory management. This working capital efficiency is a structural advantage, but the thin current ratio of 0.89 suggests reliance on this float to meet short-term obligations.

The sharp increase in D/EBITDA is partly due to seasonal working capital needs and acquisition activity, as total debt grew 58% to $11.7B. However, interest coverage of 17.99x suggests that operating income comfortably covers interest expense, even with higher rates. The negative equity position makes traditional D/E ratios meaningless, but the absolute debt level relative to EBITDA warrants monitoring, especially if cash flow turns negative as in 2027Q1.

The current ratio below 1.0 suggests that current liabilities exceed current assets, but this is common in distribution models where the negative CCC provides a funding source. The quick ratio of 0.52 highlights inventory dependence, but inventory turns quickly. Under a severe stress scenario, such as a disruption in supplier credit, the liquidity buffer appears thin, though the company's scale and access to capital markets may mitigate this risk.